Daniel T. Scavilla
Known title: DirectorCIK: 0001642439
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RBC Lowers Globus Medical Price Target to $85. RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.
Transaction History
| XRAY | ▼ Sell | Tax Withholding | 4,095 | $42K | 5/22/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 145,089 | $0 | 3/4/2026 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 1,194 | $16K | 2/24/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 246 | $0 | 1/9/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 224 | $0 | 10/10/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 210 | $0 | 7/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 13,880 | $0 | 5/22/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 3,385 | $0 | 2/24/2025 | View on chart |
| GMED | ▲ Buy | Option Exercise | 50,000 | $2.2M | 11/21/2024 | View on chart |
| GMED | ▼ Sell | Open Market | 130,000 | $11.1M | 11/21/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 80,000 | $3.5M | 11/21/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 30,000 | $1.3M | 11/6/2024 | View on chart |
| GMED | ▼ Sell | Open Market | 60,000 | $4.8M | 11/6/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 30,000 | $788K | 11/6/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage
XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.